Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Identification of Altered Developmental Pathways in Human Juvenile HD iPSC With 71Q and 109Q Using Transcriptome Profiling.

Świtońska K, Szlachcic WJ, Handschuh L, Wojciechowski P, Marczak Ł, Stelmaszczuk M, Figlerowicz M, Figiel M.

Front Cell Neurosci. 2019 Jan 18;12:528. doi: 10.3389/fncel.2018.00528. eCollection 2018.


The Generation of Mouse and Human Huntington Disease iPS Cells Suitable for In vitro Studies on Huntingtin Function.

Szlachcic WJ, Wiatr K, Trzeciak M, Figlerowicz M, Figiel M.

Front Mol Neurosci. 2017 Aug 8;10:253. doi: 10.3389/fnmol.2017.00253. eCollection 2017. Erratum in: Front Mol Neurosci. 2017 Sep 28;10 :312.


Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway.

Szlachcic WJ, Switonski PM, Krzyzosiak WJ, Figlerowicz M, Figiel M.

Dis Model Mech. 2015 Sep;8(9):1047-57. doi: 10.1242/dmm.019406. Epub 2015 Jun 18.


Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells.

Wiatr K, Szlachcic WJ, Trzeciak M, Figlerowicz M, Figiel M.

Mol Neurobiol. 2018 Apr;55(4):3351-3371. doi: 10.1007/s12035-017-0477-7. Epub 2017 May 11. Review.


Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.

Juopperi TA, Kim WR, Chiang CH, Yu H, Margolis RL, Ross CA, Ming GL, Song H.

Mol Brain. 2012 May 21;5:17. doi: 10.1186/1756-6606-5-17.


HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.

Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, Svendsen CN.

Hum Mol Genet. 2015 Jun 1;24(11):3257-71. doi: 10.1093/hmg/ddv080. Epub 2015 Mar 3.


The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.

van Hagen M, Piebes DGE, de Leeuw WC, Vuist IM, van Roon-Mom WMC, Moerland PD, Verschure PJ.

BMC Genomics. 2017 May 12;18(1):373. doi: 10.1186/s12864-017-3745-z.


Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.

Chae JI, Kim DW, Lee N, Jeon YJ, Jeon I, Kwon J, Kim J, Soh Y, Lee DS, Seo KS, Choi NJ, Park BC, Kang SH, Ryu J, Oh SH, Shin DA, Lee DR, Do JT, Park IH, Daley GQ, Song J.

Biochem J. 2012 Sep 15;446(3):359-71. doi: 10.1042/BJ20111495.


FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.

Liu Y, Qiao F, Leiferman PC, Ross A, Schlenker EH, Wang H.

Hum Mol Genet. 2017 Nov 15;26(22):4416-4428. doi: 10.1093/hmg/ddx327.


Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.

Choudhury KR, Das S, Bhattacharyya NP.

J Proteomics. 2016 Jan 30;132:155-66. doi: 10.1016/j.jprot.2015.11.007. Epub 2015 Nov 12.


Three Huntington's Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes.

Jacquet L, Neueder A, Földes G, Karagiannis P, Hobbs C, Jolinon N, Mioulane M, Sakai T, Harding SE, Ilic D.

PLoS One. 2015 May 20;10(5):e0126860. doi: 10.1371/journal.pone.0126860. eCollection 2015.


Chromosomal instability during neurogenesis in Huntington's disease.

Ruzo A, Croft GF, Metzger JJ, Galgoczi S, Gerber LJ, Pellegrini C, Wang H Jr, Fenner M, Tse S, Marks A, Nchako C, Brivanlou AH.

Development. 2018 Jan 29;145(2). pii: dev156844. doi: 10.1242/dev.156844.


Selective roles of normal and mutant huntingtin in neural induction and early neurogenesis.

Nguyen GD, Gokhan S, Molero AE, Mehler MF.

PLoS One. 2013 May 14;8(5):e64368. doi: 10.1371/journal.pone.0064368. Print 2013.


Modeling Huntington׳s disease with patient-derived neurons.

Mattis VB, Svendsen CN.

Brain Res. 2017 Feb 1;1656:76-87. doi: 10.1016/j.brainres.2015.10.001. Epub 2015 Oct 13. Review.


Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells.

Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C, Chang DJ, Kwon J, Oh SH, Shin DA, Kim HS, Do JT, Lee DR, Kim M, Kang KS, Daley GQ, Brundin P, Song J.

Stem Cells. 2012 Sep;30(9):2054-62. doi: 10.1002/stem.1135. Erratum in: Stem Cells. 2012 Nov;30(11):2602.


Cellular Models: HD Patient-Derived Pluripotent Stem Cells.

Geater C, Hernandez S, Thompson L, Mattis VB.

Methods Mol Biol. 2018;1780:41-73. doi: 10.1007/978-1-4939-7825-0_4.


Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.

Chiu FL, Lin JT, Chuang CY, Chien T, Chen CM, Chen KH, Hsiao HY, Lin YS, Chern Y, Kuo HC.

Hum Mol Genet. 2015 Nov 1;24(21):6066-79. doi: 10.1093/hmg/ddv318. Epub 2015 Aug 11.


Human Huntington's Disease iPSC-Derived Cortical Neurons Display Altered Transcriptomics, Morphology, and Maturation.

Mehta SR, Tom CM, Wang Y, Bresee C, Rushton D, Mathkar PP, Tang J, Mattis VB.

Cell Rep. 2018 Oct 23;25(4):1081-1096.e6. doi: 10.1016/j.celrep.2018.09.076.


Characterization of forebrain neurons derived from late-onset Huntington's disease human embryonic stem cell lines.

Niclis JC, Pinar A, Haynes JM, Alsanie W, Jenny R, Dottori M, Cram DS.

Front Cell Neurosci. 2013 Apr 5;7:37. doi: 10.3389/fncel.2013.00037. eCollection 2013.


Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes.

Conforti P, Besusso D, Bocchi VD, Faedo A, Cesana E, Rossetti G, Ranzani V, Svendsen CN, Thompson LM, Toselli M, Biella G, Pagani M, Cattaneo E.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E762-E771. doi: 10.1073/pnas.1715865115. Epub 2018 Jan 8. Erratum in: Proc Natl Acad Sci U S A. 2018 Feb 20;:.

Supplemental Content

Support Center